NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON

Vendor Intelligence Report: Huaian Hanyou Peptide

Published 12 Nov 2026. 36-page investigative report on who is behind Huaian Hanyou Peptide: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Huaian Hanyou Peptide is product-specific and channel-sensitive, not a simple pass/fail vendor. Across 76 Finnrick lab tests, the record is 49 pass / 27 fail, a 64% overall pass rate. GHK-Cu is the cleanest signal, Retatrutide and Tirzepatide are directionally usable only with batch verification, and MOTS-c plus TB-500 are fail-heavy avoid signals. Under stricter grading, ratings contract.

The channel problem is sharper than the average score. Global Sources is the best-supported starting point, but its own disclaimer discourages WhatsApp/WeChat contact. No verified official standalone domain, batch lookup, QR/authentication rail or signed COA portal was found, and public materials do not verify who controls sourcing, analytical review, QA disposition or batch release.

SGS-referenced records and storefront evidence also pull against the manufacturer narrative. The report traces the profile to a much newer Huai’an sporting-goods/rubber-products company than the supplier’s 2005, 15-year and 28-year peptide-history claims imply, then follows a dead plural-domain storefront, a live singular-domain successor with images hotlinked from the parked copycat, and a Hong Kong-branded crypto-only storefront that once displayed the same Chinese identifiers before that text disappeared.

The operational risk is concrete: brand-search traffic is being captured by Rutgers and other doorway pages that redirect to WhatsApp, while community reports describe fee-ladder demands, non-updating tracking, an unlabeled order and disputed Selena/lucky/Mia McGrat contacts. The full report separates proven anchors from open leads and gives product/channel guidance rather than a blanket verdict.

Inside the full report:

  • Per-product pass/fail rates, rating trajectories and methodology-divergence charts for all 8 tested products
  • Corporate-claims timeline comparing registry-derived entity fields with Global Sources longevity, factory, OEM and sales claims
  • Channel-authentication map covering Global Sources, Facebook pages, the parked plural domain and the live singular-domain storefront
  • Copycat/successor storefront evidence, including RDAP dates, BBB report context and image-URL provenance
  • Doorway-SEO and sister-brand analysis covering Rutgers-to-WhatsApp redirects and the Moh Peptides Supply crypto-checkout lead

Risk assessment

  • Copycat / brand-confusion risk — high: No verified official domain or authentication rail; huaianhanyoupeptides.com is parked after BBB #1299344, and huaianhanyoupeptide.com is live with HK WhatsApp, Gmail, Shanghai claim and images hotlinked from the dead copycat.
  • Fee-ladder fraud under the brand — high: Fresh r/saferpeptides report describes US$500 lost to Mia McGrat followed by a US$250 stamp/delivery demand, matching the documented advance-fee pattern.
  • Doorway-SEO brand-capture risk — high: Rutgers LCSR and other brand-targeted pages redirect through peptideai.xyz to WhatsApp, so search-origin buyers can be captured by sellers not tied to the Finnrick-tested supply.
  • Genuine-channel fulfilment reliability concern — high: Community reports describe months-long delays, non-updating tracking, poor communication, mis-ships, a US$3,000 unlabeled order and Selena/lucky complaints.
  • Product-specific quality failure — MOTS-c and TB-500 — high: Finnrick rates MOTS-c at 30.38% with 5 tests and TB-500 at 34.63% with 5 tests; both are fail-heavy avoid signals.
  • Product-specific quality weakness — BPC-157, Tesamorelin and Ipamorelin — medium: Finnrick rates BPC-157 at 46.97%, Tesamorelin at 51.16% and Ipamorelin at 61.16%; these are weak or thin lines, not a blanket vendor failure.
  • Corporate identity and manufacturer-claims mismatch — medium: 2024 sporting-goods entity and RMB 300,000 capital conflict with 2005/15/28-year peptide-history claims, factory/staff claims, US$8–9M sales and inconsistent OEM/small-order fields.
  • Sister-brand / crypto-only storefront concern — medium: Moh Peptides Supply was indexed with the same USCC and He Fengjie, later scrubbed that text, and accepts only BTC/USDT; the entity link is material but single-source.